Publication Name	World Journal of Clinical Oncology
Manuscript ID	61176
Country	Ireland

Received	2020-11-26 19:48
Peer-Review Started	2020-11-26 19:48
To Make the First Decision
Return for Revision	2020-12-11 18:57
Revised	2021-01-02 09:54
Second Decision	2021-01-28 06:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-03-01 16:15
Articles in Press	2021-03-01 16:15
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-03-06 23:13
Typeset the Manuscript	2021-03-10 05:25
Publish the Manuscript Online	2021-03-11 12:05

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Overview of recent advances in metastatic triple negative breast cancer
Manuscript Source	Invited Manuscript
All Author List	David O'Reilly, Maha Al Sendi and Catherine M Kelly
Funding Agency and Grant Number
Corresponding Author	David O'Reilly, MBChB, MRCP, Academic Fellow, Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 1, Ireland. oreilld8@tcd.ie
Key Words	Triple negative breast cancer; Immunotherapy; Poly (adenosine diphosphate-ribose) polymerase inhibitors; Breast cancer
Core Tip	Despite recent advances, chemotherapy remains integral to the management of advanced triple negative breast cancer. Immunotherapy and poly (adenosine diphosphate-ribose) polymerase inhibitors have shown much promise but have yet to demonstrate a proven overall survival benefit in this disease. Antibody drug conjugates and other targeted therapies may ultimately prove to be the next frontier in treating this illness.
Publish Date	2021-03-11 12:05
Citation	O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 2021; 12(3): 164-182
URL	https://www.wjgnet.com/2218-4333/full/v12/i3/164.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i3.164

Full Article (PDF)	WJCO-12-164.pdf
Full Article (Word)	WJCO-12-164.docx
Manuscript File	61176-Review-FilipodiaCL.docx
Answering Reviewers	61176-Answering reviewers.pdf
Audio Core Tip	61176-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	61176-Conflict-of-interest statement.pdf
Copyright License Agreement	61176-Copyright license agreement.pdf
Peer-review Report	61176-Peer-review(s).pdf
Scientific Misconduct Check	61176-Bing-Huang P-1.png
Scientific Misconduct Check	61176-Bing-Fan JR-2.png
Scientific Misconduct Check	61176-Scientific misconduct check.pdf
Scientific Editor Work List	61176-Scientific editor work list.pdf